Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (Ab209538)

特异性

This antibody mainly recognizes alpha synuclein Filament, but also has weak cross-reactivity with alpha synuclein Monomer.

Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (ab209538) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Dot blot, ICC/IF, IHC-P in human samples. Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (ab209538) has been cited over 73 times in peer reviewed journals and is trusted by the scientific community. Abcam's high quality manufacturing and validation processes ensure Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (ab209538) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. Anti-Alpha-synuclein aggregate antibody (Anti-SNCA antibody) [MJFR-14-6-4-2] - Conformation-Specific (ab209538) has 6 independent reviews from customers. Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (ab209538) specifically detects Alpha-synuclein aggregate (UniProt ID: P37840; Molecular weight: 14kDa) and is sold in 100 µL and 1 mL selling sizes. Conjugation-ready, carrier free format available for antibody clone MJFR-14-6-4-2 - ab214033. Antibody clone MJFR-14-6-4-2 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor® 488, Alexa Fluor® 647, Biotin, Alexa Fluor® 594 ( ab216124, ab216309, ab227047, ab283628 ). Anti-Alpha-synuclein aggregate antibody [MJFR-14-6-4-2] - Conformation-Specific (ab209538) was developed by Abcam in partnership with the Michael J. Fox Foundation for Parkinson's Research. ab209538 is not suitable for WB or other denaturing conditions, as it is conformation-specific. This antibody is useful for studying Parkinson's disease and other synucleinopathies including dementia with Lewy bodies and multiple system atrophy. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies. Collaborations This antibody was developed with support from The Michael J. Fox Foundation.